Zacks Investment Research upgraded shares of Q BioMed (OTCMKTS:QBIO) from a hold rating to a buy rating in a report published on Wednesday. The firm currently has $2.25 price target on the stock.

According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “

Separately, Roth Capital lowered shares of Q BioMed from a buy rating to a neutral rating and decreased their price objective for the stock from $6.75 to $1.85 in a report on Thursday, November 29th.

OTCMKTS:QBIO opened at $1.92 on Wednesday. Q BioMed has a 52 week low of $1.67 and a 52 week high of $5.03.

Q BioMed Company Profile

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.

See Also: What is the balance sheet?

Get a free copy of the Zacks research report on Q BioMed (QBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.